公司資料
Genmab 股價、新聞與催化劑
- 股票代碼:
- GMAB
- 交易所:
- NASDAQ
- 產業:
- Antibody Drugs
- 所在地:
- Copenhagen, Denmark
股票表現
34.55 USD (-3.15%)
收盤價
最後更新: 2026年10月1日
14.6B USD
市值
股價為何變動
截至 2026年10月1日，GMAB 下跌 3.15%，收於 $34.55。目前新聞監測窗口內未發現新的同公司新聞。
公司概覽
Antibody-Focused Biotechnology Company
Genmab is a global biotechnology company focused on creating differentiated antibody therapeutics for cancer and other serious diseases. It combines internal antibody discovery, proprietary engineering platforms, clinical development, commercialization, and a large network of pharmaceutical partnerships.
Proprietary Antibody Technologies
The company's technology base includes DuoBody bispecific antibodies, HexaBody antibodies with enhanced complement activation, DuoHexaBody constructs, and HexElect conditional effector-function technology. These platforms are designed to generate new mechanisms of action and can support both wholly owned programs and partnered medicines.
Commercial and Co-Commercialized Medicines
Genmab's direct commercial portfolio includes EPKINLY/TEPKINLY, an epcoritamab-based bispecific antibody for B-cell malignancies, and Tivdak for cervical cancer. The company shares economics and commercialization responsibilities with partners in selected markets while retaining the ability to build its own global oncology organization.
Royalty-Based Portfolio
Antibodies created with Genmab technology support a significant royalty business. Products contributing to this model include DARZALEX, Kesimpta, TEPEZZA, RYBREVANT, TECVAYLI, TALVEY, and BIZENGRI, providing diversified exposure across oncology, immunology, and rare disease without requiring Genmab to fund every commercial infrastructure independently.
Late-Stage Oncology Pipeline
The late-stage proprietary pipeline is led by Rina-S, an antibody-drug conjugate targeting folate receptor alpha, and petosemtamab, an EGFRxLGR5 bispecific antibody added through the acquisition of Merus. Epcoritamab is also being developed across additional lymphoma settings and treatment lines, making lifecycle expansion an important part of the portfolio.
未來催化劑
- Phase 3 RAINFOL-02 data for Rina-S in platinum-resistant ovarian cancer during 2026.
- Phase 3 data from one or both LiGeR-HN studies of petosemtamab in head and neck squamous cell carcinoma during 2026.
近期新聞
新聞標題由機器翻譯，詳情為英文原文。
相似股票
商業成熟度、治療領域或催化劑模式相近的同業公司。